RxDoctor Payments Data

Wayne Margolis, MD

Interventional Cardiology · Beaumont, TXNPI 1609871334

Payments from drug & device makers

$19,356in general payments, 2019–2025

Across 392 payments — averaging $49.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$8K
  • Boehringer Ingelheim$3K
  • Boston Scientific$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$959
  • Merck$862
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$1,0005%
  • Speaking & faculty fees$10,48854%
  • Food & beverage$7,79640%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,356 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$118,353
Medicare patients
714
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban393$413,748
JardianceEmpagliflozin137$133,469
EntrestoSacubitril/Valsartan91$110,725
FarxigaDapagliflozin Propanediol72$78,585
MultaqDronedarone Hcl34$59,421
Repatha SureclickEvolocumab50$49,383
Repatha PushtronexEvolocumab32$35,334
NexletolBempedoic Acid51$34,085
XareltoRivaroxaban36$33,438
VascepaIcosapent Ethyl44$31,675
WegovySemaglutide15$25,087
RybelsusSemaglutide19$23,521
Praluent PenAlirocumab15$17,694
Ezetimibe681$16,340
OzempicSemaglutide16$15,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8,465$413,748393 claims
Boehringer IngelheimJardiance$2,538$133,469137 claims
NovartisEntresto$959$110,72591 claims
AstraZenecaFarxiga$134$78,58572 claims
Novo NordiskWegovy, Rybelsus, Ozempic$18$63,71850 claims
Sanofi-aventis U.S. LLCMultaq$228$59,42134 claims
Esperion Therapeutics, Inc.Nexletol$172$34,08551 claims
Johnson & JohnsonXarelto$454$33,43836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →